Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $68.3 million.

  • Vanda Pharmaceuticals' Accounts Payables rose 7473.52% to $68.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $68.3 million, marking a year-over-year increase of 7473.52%. This contributed to the annual value of $68.3 million for FY2025, which is 7473.52% up from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Accounts Payables stood at $68.3 million, which was up 7473.52% from $47.6 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Accounts Payables peaked at $68.3 million during Q4 2025, and registered a low of $26.1 million during Q1 2021.
  • Over the past 5 years, Vanda Pharmaceuticals' median Accounts Payables value was $39.2 million (recorded in 2024), while the average stood at $41.7 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Accounts Payables skyrocketed by 9687.42% in 2022 and then plummeted by 3644.2% in 2023.
  • Vanda Pharmaceuticals' Accounts Payables (Quarter) stood at $34.4 million in 2021, then skyrocketed by 32.27% to $45.6 million in 2022, then fell by 15.57% to $38.5 million in 2023, then rose by 1.63% to $39.1 million in 2024, then skyrocketed by 74.74% to $68.3 million in 2025.
  • Its Accounts Payables was $68.3 million in Q4 2025, compared to $47.6 million in Q3 2025 and $57.1 million in Q2 2025.